#328 RXs for Orexins? The efficacy and safety of orexin antagonists for insomnia
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
- 7 systematic reviews of randomized, controlled trials (RCTs).1-7 Focusing on the most recent and comprehensive. Results statistically significant unless indicated.
- Systematic review1 (13 RCTs, 7875 patients, mean age ~55 years) over ~1-3 months:
- Sleep diary outcomes; compared to placebo, orexin antagonists changed:
- Sleep onset: ~9 minutes faster [example: Baseline 65 minutes, 47 minutes with orexins versus 56 minutes (placebo)].
- Total sleep time: Increased ~19 minutes.
- Time awake after falling asleep: ~9 minutes less.
- Sleep quality: Improved ~5% (example improved 0.2 points on a 4-point scale, not likely clinically meaningful).8
- No clinical difference: Awakenings or feeling refreshed on awakening.
- Other reviews2-6 found similar.
- Response on insomnia score:6 55% versus 42% (placebo), NNT=8.
- One RCT with 12 months follow-up found similar.9
- Adverse events:
- Stopping due to adverse effects: No difference.2,3,7
- Most common adverse events:1
- Somnolence 8.3% versus 2.2% (placebo), number needed to harm (NNH)=16.
- Fatigue, dry mouth, abnormal dreams each ~2-3% versus 1% placebo.
- Effects on falls unclear (4 small observational studies in hospitals): Range from associated with increased fall risk to decreased.10-13
- One observational study suggests fracture risk similar between suvorexant and z-drugs.14
- Sleep diary outcomes; compared to placebo, orexin antagonists changed:
- RCT comparing 5 and 10mg Lemborexant to Zolpidem ER:15
- Sleep onset: Lemborexant ~6 minutes better.
- Time awake after falling asleep: Range from no difference to zolpidem ~15 minutes better.
- Proportion of time asleep: No difference
- Dropout due to adverse events: 0.9% versus 2.7% zolpidem.
- Limitations
- RCTs industry sponsored, use of run-ins, incomplete outcome reporting.
- Similar efficacy16 in those >65.
- Limited evidence suggests minimal withdrawal symptoms.2,13,15,17
- Abuse potential not formally assessed in insomnia RCTs.
- Orexin inhibitors have been associated with sleep paralysis/complex sleep behaviors (example “sleep-driving”).18
- Non-pharmacologic sleep restriction therapy is effective.19
- Lemborexant (available in Canada) price: $48/30 tablets.20
Helpful review on relatively new med
8.3% somnolence could be an issue
These drugs may not be very useful
good new data
Non pharmacological treatment should be emphasized .
One of my pts felt adverse effects and self stopped this medication .
This information has been helpful
going thru this, its difficult to decide whether such small benefits outweighs the risks of getting side effects